NASDAQ:RNAC Cartesian Therapeutics (RNAC) Stock Price, News & Analysis $17.49 +0.91 (+5.49%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$16.22▼$17.7650-Day Range$15.77▼$36.5852-Week Range$11.66▼$42.60Volume54,586 shsAverage Volume91,777 shsMarket Capitalization$311.32 millionP/E RatioN/ADividend YieldN/APrice Target$43.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Cartesian Therapeutics alerts: Email Address Cartesian Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside150.6% Upside$43.83 Price TargetShort InterestBearish28.82% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.63Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom $2.67 to ($2.89) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.72 out of 5 starsMedical Sector471st out of 936 stocksPharmaceutical Preparations Industry215th out of 436 stocks 4.4 Analyst's Opinion Consensus RatingCartesian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCartesian Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cartesian Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted28.82% of the float of Cartesian Therapeutics has been sold short.Short Interest Ratio / Days to CoverCartesian Therapeutics has a short interest ratio ("days to cover") of 13.2, which indicates bearish sentiment.Change versus previous monthShort interest in Cartesian Therapeutics has recently increased by 73.91%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCartesian Therapeutics does not currently pay a dividend.Dividend GrowthCartesian Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RNAC. Previous Next 3.1 News and Social Media Coverage News SentimentCartesian Therapeutics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cartesian Therapeutics this week, compared to 2 articles on an average week.Search Interest4 people have searched for RNAC on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows3 people have added Cartesian Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cartesian Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders61.10% of the stock of Cartesian Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.95% of the stock of Cartesian Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cartesian Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cartesian Therapeutics are expected to decrease in the coming year, from $2.67 to ($2.89) per share.Read more about Cartesian Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Cartesian Therapeutics Stock (NASDAQ:RNAC)Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.Read More RNAC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RNAC Stock News HeadlinesJuly 8, 2024 | globenewswire.comCartesian Therapeutics Announces New Employment Inducement GrantsJuly 2, 2024 | globenewswire.comCartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal MalikJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 2, 2024 | investors.comCartesian Therapeutics Plummets Despite 'Watershed Moment' For CAR-T DrugsJuly 2, 2024 | reuters.comCartesian Therapeutics autoimmune disorder therapy meets main goal of mid-stage studyJuly 2, 2024 | globenewswire.comCartesian Therapeutics Announces $130 Million Private Placement Equity FinancingJuly 2, 2024 | globenewswire.comCartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus ErythematosusJuly 2, 2024 | globenewswire.comCartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia GravisJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 6, 2024 | globenewswire.comCartesian Therapeutics Announces New Employment Inducement GrantMay 24, 2024 | msn.comMizuho Initiates Coverage of Cartesian Therapeutics (RNAC) with Buy RecommendationMay 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cartesian Therapeutics Amidst Promising Clinical Advancements and Strategic PositioningMay 24, 2024 | msn.comMizuho starts Cartesian at buy, cites lead drug assetMay 22, 2024 | msn.comCartesian stock climbs 8% on FDA regenerative therapy designationMay 22, 2024 | markets.businessinsider.comCartesian: FDA Grants Regenerative Medicine Advanced Therapy Designation For Descartes-08May 22, 2024 | globenewswire.comCartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia GravisMay 17, 2024 | edition.cnn.comCartesian Therapeutics, Inc.May 13, 2024 | globenewswire.comCartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQSee More Headlines Receive RNAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cartesian Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Estimated)8/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RNAC Previous SymbolNASDAQ:RNAC CUSIPN/A CIK1453687 Webselectabio.com Phone617-923-1400Fax617-924-3454Employees64Year FoundedN/APrice Target and Rating Average Stock Price Target$43.83 High Stock Price Target$50.00 Low Stock Price Target$39.00 Potential Upside/Downside+162.9%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-219,710,000.00 Net Margins-983.93% Pretax Margin-1,057.17% Return on EquityN/A Return on Assets-18.77% Debt Debt-to-Equity RatioN/A Current Ratio3.03 Quick Ratio3.03 Sales & Book Value Annual Sales$26 million Price / Sales11.41 Cash FlowN/A Price / Cash FlowN/A Book Value($82.38) per share Price / Book-0.20Miscellaneous Outstanding Shares17,800,000Free Float6,923,000Market Cap$296.73 million OptionableOptionable Beta0.66 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Carsten Brunn Ph.D. (Age 52)President, CEO & Director Comp: $4.67MMr. Blaine T. Davis (Age 49)Chief Financial Officer Comp: $2.49MDr. Metin Kurtoglu M.D. (Age 45)Ph.D., Chief Technology Officer Comp: $398.28kKey CompetitorsRelay TherapeuticsNASDAQ:RLAYArcutis BiotherapeuticsNASDAQ:ARQTDisc MedicineNASDAQ:IRONCollegium PharmaceuticalNASDAQ:COLLNurix TherapeuticsNASDAQ:NRIXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpSold 297,406 shares on 7/26/2024Ownership: 0.112%Hall Laurie J TrusteeSold 51,016 shares on 7/22/2024Ownership: 0.010%Artal Group S.A.Bought 9,136,635 shares on 5/17/2024Ownership: 171.098%American International Group Inc.Bought 56,202 shares on 5/14/2024Ownership: 1.052%Vanguard Group Inc.Bought 6,315,113 shares on 5/10/2024Ownership: 118.172%View All Insider TransactionsView All Institutional Transactions RNAC Stock Analysis - Frequently Asked Questions How have RNAC shares performed this year? Cartesian Therapeutics' stock was trading at $20.6820 at the start of the year. Since then, RNAC stock has decreased by 15.4% and is now trading at $17.49. View the best growth stocks for 2024 here. How were Cartesian Therapeutics' earnings last quarter? Cartesian Therapeutics, Inc. (NASDAQ:RNAC) released its quarterly earnings data on Wednesday, May, 8th. The company reported ($1.97) EPS for the quarter, missing analysts' consensus estimates of ($0.81) by $1.16. The firm had revenue of $5.84 million for the quarter. When did Cartesian Therapeutics' stock split? Cartesian Therapeutics's stock reverse split before market open on Friday, April 5th 2024. The 1-30 reverse split was announced on Friday, April 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are Cartesian Therapeutics' major shareholders? Top institutional shareholders of Cartesian Therapeutics include Bank of New York Mellon Corp (0.11%) and Hall Laurie J Trustee (0.01%). View institutional ownership trends. How do I buy shares of Cartesian Therapeutics? Shares of RNAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RNAC) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cartesian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cartesian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
